Gore announces first US enrolment for the Viafort vascular stent iliofemoral study

Investigational GORE® VIAFORT Vascular Stent

Gore has announced that the first US patient has been enrolled in a prospective, non-randomised, multicentre, single-arm study with five-year follow-up to evaluate the investigational Gore Viafort vascular stent for the treatment of symptomatic iliofemoral venous obstruction.

The first US patient was enrolled by David J Dexter II at Sentara Vascular Specialists, Norfolk, USA. “With several US Food and Drug Administration [FDA]-approved stents on the market, there was a concern that enrolment in another iliac vein stent trial would be difficult. Designed with the unique qualities for flexibility and radial force, the Viafort device is compelling to use in a clinical trial,” he said.

A company press release notes that the Gore Viafort vascular stent utilises the Gore expanded polytetrafluoroethylene (ePTFE) technology in conjunction with a single wire, sinusoidal-wound nitinol frame. The Gore Viafort vascular stent iliofemoral study is evaluating the device in a treatment range of 10 to 20mm diameter for iliofemoral veins. The study is being conducted in the USA under an approved investigational device exemption (IDE).


Please enter your comment!
Please enter your name here